At LSC we specialise only in Life Sciences and always keep up to date with leading news, projects and all that’s going on in the industry. As the sector sees continued rapid growth it’s easy to miss some of the major announcements. To make things easier and to ensure you too are well informed we’ve selected and summarised this month’s top Irish Life Science industry news stories below.
AbbVie to buy Irish-headquartered Allergan
US drugmaker AbbVie has agreed to buy Allergan, the Irish-domiciled maker of Botox, in a $63 billion (€55.3 billion) deal that is the sector’s latest transaction driven by the need to replenish drug pipelines. AbbVie employs 600 in Ireland, while Allergan employs 1,700.
“With our enhanced growth platform to fuel industry-leading growth, this strategy allows us to diversify AbbVie’s business while sustaining our focus on innovative science and the advancement of our industry-leading pipeline well into the future,” said Richard Gonzalez, chairman and chief executive at AbbVie. Full article >>
Stryker to invest €200m in R&D in Cork facilities
Medtech company Stryker is to invest more than €200 million at research and development in three of its Cork facilities. The funding is part of the company’s drive to develop next-generation products and services across its medical surgical, orthopaedics and neurotechnology and spine units.
The company has been in operation in Ireland for more than 20 years, has six locations and employs more than 3,500 people.
“Our team in Ireland has built considerable research and development and new product development capabilities through the partnership of multiple divisions over the past 20 years in an effort to serve multiple market segments,” said Stryker’s Spencer Stiles. Full article >>
Construction works begin on €325 million WuXi Biologics Dundalk facility
Construction work has begun on the 52-acre €325 million WuXi Biologics facility in Co Louth. The Dundalk-based, 48,000 square metres site is set to become the world’s largest single-use biologics manufacturing facility.
The facility will be WuXi’s first outside of China and is scheduled to enter full commercial production by 2022. Full article >>
Thermo Fisher snaps up GSK site in Ireland as part of its expansion campaign
Thermo Fisher Scientific, which has been rapidly expanding its drug production, has struck a deal to buy a GlaxoSmithKline active pharmaceutical ingredient site in Ireland for €90 million.
Massachusetts-based Thermo Fisher will pick up the 400 employees at the Cork site, which has 270 cubic meters of reactor capacity, 10 production buildings, an R&D pilot plant and labs.
The operation makes specialized ingredients for GSK drugs that target diseases including cancer, depression and Parkinson’s. After the deal closes by the end of the year, Thermo Fisher will continue to produce APIs for GSK. Thermo Fisher said it intends to expand production at the Cork site in line with its other expansion plans. Full article >>
90% Funded Life Science courses available under Springboard+ Initiative
In response to the recognised skills shortage in the Irish Life Science industry there are currently fantastic courses available through the Springboard+ initiative in the sector. Full article>>
If you’re looking to be part of this thriving sector, click below to explore contract opportunities in the Life Sciences with LSC today!